Day One Biopharmaceuticals, Inc. (DAWN) 8-K Current Report: March 6, 2026
Filed: March 6, 2026
Health Care
Pharmaceutical PreparationsDay One Biopharmaceuticals, Inc. (DAWN) 8-K current report filed with SEC EDGAR on March 6, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 8.01: Other Events
Day One Biopharmaceuticals, Inc. 8-K Mar 6, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • Servier Pharmaceuticals (Parent) to acquire all DAWN shares at $21.50/share cash via tender offer — no financing condition
- • Tender offer launches within 15 business days of March 6, 2026; expires 20 business days after commencement unless extended
- • Deal closes without shareholder vote under DGCL Section 251(h) once majority of shares tendered; back-end merger converts remaining shares at same $21.50 price
- • All unvested options and RSUs accelerate and cash out at close; options receive spread vs. $21.50 exercise price
- • Termination fee of $87.7M payable by DAWN to Parent under specified break scenarios; outside date December 6, 2026, extendable 150 days for regulatory approval
Item 8.01 · Other Events
- • DAWN entering merger agreement with unnamed "Parent" — acquisition via tender offer structure announced March 6, 2026
- • Tender offer (Schedule TO) not yet commenced; formal offer docs + DAWN's Schedule 14D-9 recommendation still pending SEC filing
- • Stockholders should await tender offer materials before deciding whether to tender shares — no price or deal terms disclosed in this item
- • Key closing risks: shareholder tender threshold, regulatory conditions, competing bids, and potential litigation
Other Day One Biopharmaceuticals, Inc. 8-K Filings
Get deeper insights on Day One Biopharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.